The clear advantage in relapse detection

Clarity Logo Placeholder

Foresight CLARITY™

delivers early and accurate response assessment using ultra-sensitive ctDNA-MRD technology

See Clearly.
Act Decisively.

Foresight CLARITY is an ultra-sensitive, liquid-biopsy platform that detects minimal residual disease (MRD) across multiple indications using our proprietary PhasED-Seq™ circulating tumor DNA (ctDNA) technology.

Our research to date shows that Foresight CLARITY can detect residual disease earlier than imaging and conventional liquid biopsy methods, Foresight CLARITY offers unprecedented insight into cancer relapse and recurrence.

Patient Journey

30-40% of DLBCL patients are likely to relapse 1-2 years after first-line therapy.1

Foresight CLARITY may predict relapse risk immediately at the end of treatment. That’s up to 200 days sooner than relying on PET/CT for relapse diagnosis.2

Foresight CLARITY

For Lymphoma


Foresight CLARITY for Lymphoma is an off-the-shelf MRD assay that detects extremely low levels of ctDNA from plasma based on patient-specific phased variants.


  • Fixed, off-shelf assay for fast turnaround from our central CLIA-registered lab
  • Accepts plasma from standard blood draw volumes
  • Pre-treatment plasma for phased variants – tumor sample accepted but not required
  • Report delivered with MRD status and ctDNA levels
  • Option to include panel of clinically-relevant SNV and CNV results


  • Large B-cell lymphoma (LBCL/DLBCL)
  • Follicular lymphoma
  • Hodgkin’s lymphoma
  • Other B-cell malignancies

Foresight CLARITY

For Solid Tumor


Foresight CLARITY for Solid Tumor is a custom, tumor-informed MRD assay that offers a high degree of sensitivity based on patient-specific phased variants that are identified with whole-genome sequencing.


  • Custom assay developed and run at our central CLIA-registered lab
  • Accepts plasma from standard blood draw volumes
  • Report delivered with MRD status and ctDNA levels
  • Option to include panel of clinically-relevant SNVs and tumor-specific variants in report


  • Pan-cancer for translational research

Foresight CLARITY is for research use only. Not intended for use in diagnostic procedures.

Interested in other indications? Contact us to discuss.

Contact Us
See relapses that others miss
Foresight CLARITY <1 part per million
Conventional SNV-based Methods Up to 1 part per ten thousand

Lower limit of detection.
Higher standards.

LOD95: Limit of detection with 95% confidence.

  • >90% Clinical sensitivity at EOT2
  • >97% Clinical specificity at EOT2
Watch Video

Performance characteristics shown for lymphoma. These performance characteristics have not been reviewed by the FDA.

Clinical Utility of Foresight CLARITY

Early Outcome Prediction

MRD detected by Foresight CLARITY accurately predicted response as early as fifteen days into 2L liso-cel therapy in DLBCL.3


Accelerate Clinical Trials

Across multiple LBCL studies, Foresight CLARITY accurately stratified patient response at end of treatment, correlating analytical sensitivity with clinical sensitivity. Results showed that integrating MRD as a surrogate endpoint for response assessment may accelerate clinical trials by up to 12 months as opposed to PFS alone.4,5

Accelerate Clinical Trials

Prognostic Value

A prospective real-world study powered by Foresight CLARITY found that ctDNA-MRD levels were prognostic for both progression-free survival and overall survival at interim and end-of-treatment timepoints. In cases with discordant MRD and PET/CT assessments, MRD was shown to be the more prognostic measure, suggesting opportunities for MRD to be a possible alternative to PET/CT for lymphoma response assessment.6

Prognostic Value

Read our latest data on the prognostic utility of Foresight CLARITY powered by PhasED-Seq MRD analysis in DLBCL and FL

Download now
Foresight CLARITY

Working with Foresight

From research to diagnostic development, Foresight CLARITY can help inform critical decision-making steps related to study design, execution, and analysis.

Interested in accessing Foresight CLARITY for Investigator Initiated Studies? Let’s chat.

Foresight CLARITY phases

Want to stay up to date? Join our mailing list for the latest on our research and products.


  1. Nuvvula S, Dahiya S, Patel SA. The novel therapeutic landscape for relapsed/refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk (2022)
  2. Kurtz, et al., Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma, American Society of Hematology Annual Meeting (2023)
  3. Stepan, et al., Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study, American Society of Hematology Annual Meeting (2023)
  4. Goldstein, et al., Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy, American Society of Hematology Annual Meeting (2023)
  5. Roschewski et al., End of Treatment Response Assessment After Frontline Therapy for Aggressive B-cell Lymphoma: Landmark Comparison of a Singular PET/CT scan vs Ultrasensitive Circulating Tumor DNA, American Society of Hematology Annual Meeting (2023); Sworder, et al., Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World ctDNA Study, American Society of Hematology Annual Meeting (2023)
  6. Sworder, et al., Prognostic utility of Minimal Residual Disease (MRD) after curative intent induction therapy for DLBCL: A prospective real-world ctDNA study, American Society of Hematology Annual Meeting (2023)

These performance characteristics have not been reviewed by the FDA